Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide in Recurrent Glioblastoma Multiforme
NCT00075491Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2003
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fenretinide in glioblastoma multiforme (GBM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-free survival at 6 months, Plasma and tissue concentrations of fenretinide and its metabolite at 21 days and 3 more. Started Dec 2003; status: terminated.
02
Drugs
fenretinide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00075491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075491.